0
Intercept Pharma
- 201-500 Employees
- Based in New York City, New York
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia.
Social Media Links
Intercept Pharma
Most Recent Annual Report
MOST RECENT
2019 Annual Report and Form 10K
Report Locked. Intercept Pharma has reached its limit for free report views.
